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Prdxs exhibit differences in tissue distribution, cellular localization, 
and substrate specificity, therefore demonstrating distinct roles in the 
cellular antioxidant defense system [8].
In recent years, the overexpression of Peroxiredoxins in 
breast cancer cells has been well documented [9-13]. Although 
the precise mechanism of action in these cells has not been fully 
elucidated, elevation of other antioxidants in cancer cells suggests 
that upregulation of peroxiredoxins provides a survival advantage 
to cancer cells in an environment of elevated oxidative stress. 
Additionally, research implicating oxidative stress in chemoresistance 
supports peroxiredoxins and other antioxidant proteins as potential 
candidates for therapy targets [13]. Recent studies have reported 
Prdx overexpression correlates with development, recurrence, 
and/or progression of cancers, [13-15]. Karihtala and others 
reported elevated Prdx 3-5 levels to be associated with more poorly 
differentiated tumors, and Prdx 5 with shorter survival in breast 
cancer patients [10]. They hypothesized that the increase in Prdx 
expression is induced by higher ROS levels in the cancerous state. 
However, the correlation with malignancy and disease progression 
remains a controversy as many groups have conflicting results 
[10,16,17]. Prdx2 and Prdx4 may be of particular interest since they 
are secreted proteins and may be useful biomarkers measured in 
serum samples [16]. Researchers are continuing to search for reliable 
serum biomarkers in breast cancer in the hopes of earlier detection, 
and thus better disease prognosis [16,17].
Previous research from our lab has shown overexpression of five 
of the six Prdxs at the mRNA and protein levels in the widely studied 
MCF-7 human breast cancer cell line, compared to the non-cancerous 
MCF-10A cell line [18,19]. We further showed that suppression 
of these proteins in MCF-7 cells results in reduced cell viability 
[18]. While investigation of the mechanism of Prdx regulation and 
function continues in these and other cell lines, it is essential to 
pursue Prdx studies in human tumor samples to better understand its 
physiological relevance and aberrant in vivo regulation. In addition, 
the patient-to-patient variability in Prdx expression, and significant 
evidence pointing to Prdx misregulation as an epigenetic cancer 
adaption, rather than a causal factor in carcinogenesis, suggests that 
proper controls for these experiments will be critical to determine 
when and how these Prdxs modify their regulation. As such, we 
sought to analyze Prdx protein expression in a number of patient 
samples by comparing Prdx levels in breast tumor tissue and adjacent 
normal tissue within each patient.
Abstract
Peroxiredoxin (Prdx) proteins are evolutionarily conserved thiol-
specific antioxidant enzymes that reduce various cellular peroxides, 
protecting cells from oxidative damage. Prdxs also have been 
demonstrated to play an important role in regulating redox-sensitive 
cell signaling in a number of cell processes. Prdxs have been 
implicated in cancer biology, and are upregulated in many cancers 
including breast cancer, as well as several breast cancer cell lines. 
To explore the entire Prdx family in breast cancer, we analyzed 
the expression of all six Prdx proteins in breast tumor tissue and 
adjacent normal breast tissue from 14 patients. We found that most 
patients have a marked elevation of Prdx expression in tumor tissue, 
with many patients overexpressing multiple Prdxs. Specifically, we 
found that 71% of patients overexpress Prdx1, 50% overexpress 
Prdx2, 64% overexpress Prdx3, and 57% overexpress Prdx4. In 
contrast, Prdx5 and Prdx6 are elevated in a minority of patients. 
We found no association, however, between the incidence of Prdx 
overexpression and tumor grade in this study. Our findings provide 
further evidence for Prdx elevation in breast cancer using matched 
patient samples, and support the notion that Prdx upregulation 
may provide a survival advantage to breast cancer cells, and other 
cancer cells.
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Introduction
The Peroxiredoxins are a family of evolutionarily conserved 
thiol-specific antioxidant proteins. These proteins act as peroxidase 
enzymes, reducing cellular peroxides (including hydroperoxides and 
lipid peroxides) in the presence of specific electron donors [1]. As a 
result, peroxiredoxins (Prdxs) protect cells from oxidative damage 
associated with normal cellular metabolism [2,3]. Since ROS are now 
well characterized signaling molecules, Prdxs are also recognized to 
act as modulators of redox signaling, thereby regulating a number of 
redox-sensitive processes involved in cell proliferation, differentiation, 
and apoptosis [4,5]. In mammals, there are six Prdx proteins, which 
can be subcategorized by the number of cysteines in the active site 
of the protein. The 2-Cys Prdxs (Prdx1-5) react with peroxides to 
form a disulfide bond either as dimers (Prdx1-4) or intramolecularly 
(Prdx5) [6]. In contrast, 1 -Cys Prdx (Prdx6) contains only one active 
cysteine, cannot form dimers through disulfide bond formation, and 
has the unique ability to reduce lipid peroxides [7]. The different 
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Materials & Methods
Two OncoPair INSTA-Blots membranes were purchased from 
Imgenex/Novus (San Diego, CA). These blots were cat # NBP2-
29911 (IMB-130a) and NBP2-30127 (IMB-130d). Each ready-to-
use membrane contained denatured protein lysates from ductal 
carcinomas and adjacent tissues from seven patient donors. All 
patients were females ranging in age from 36-85 years old and 
differed in the location and stage of breast cancer. As described 
(Imagenex/Novus), all protein lysates were diluted to 1 mg/ml and 
equal amounts (14 ug) were loaded onto each lane of a denaturing 
gel, electrophoresed and transferred to a PVDF membrane along 
with a molecular weight marker. Gel loading corresponds to the 
documented information.
Membranes were pre-wet in methanol and rinsed with TBST. 
They were blocked in 5% milk in TBST for one hour, incubated 
in primary antibody overnight at 4°C, rinsed 5 × 15 min in TBST, 
and incubated in the appropriate alkaline phosphatase-conjugated 
secondary antibody for one hour at room temperature. After 
additional rinses with TBST, the chemiluminescent CDP-Star 
Reagent (GE) was used as a substrate, and the blots were imaged with 
X-OMAT film (Kodak). The primary antibodies used for the analysis 
were from Abcam: anti-Prdx1 (ab59538), anti-Prdx2 (ab15572), anti-
Prdx3 (ab16751), anti-Prdx4 (ab59542), anti-Prdx5 (ab16944) anti-
Prdx6 (ab16947) (Abcam, Cambridge, MA).
Band intensities on western blots were quantified with Image J 
software. Prdx levels were normalized to control levels and relative 
fold differences between tumor and adjacent normal tissue were 
calculated for each patient. Correlation coefficients were calculated to 
compare tumor grade with incidence of Prdx elevation, for each Prdx.
Results
We analyzed two patient blots, obtained from Imgenex/Novus. Each 
blot contained paired samples of tumor/non-tumor breast tissue from 
7 patients, allowing us to analyze a total of 14 patients. Figure 1(A & B) 
shows the results of this experiment. As shown in Figure 1, almost all of 
the Prdx proteins were detectable in most of the patients, but at varying 
levels. Prdx5 was detected at the lowest levels in virtually all patients, and 
was undetectable on Blot 130a (Figure 1B).
Our experiment revealed tumor overexpression of multiple Prdx 
proteins in nearly all patients, with one patient exhibiting tumor 
overexpression of all six Prdx proteins (Figure 1A, P6). In particular, 
four patients from blot 130d (Figure 1A) and three patients from blot 
130a (Figure 1B) exhibited a very substantial increase in the expression 
of several Prdx proteins in the tumor, compared to adjacent tissue. 
Interestingly, Prdxs1-4 were overexpressed to the greatest extent in 
tumors (Figure 1) and also were overexpressed in the greatest number 
of patient tumors. The tumor-specific elevation was over five-fold in 
many patients, reaching 15X for Prdx1, 7X for Prdx2, 14X for Prdx3, 
and 16X for Prdx4. Interestingly, patient #3 (Figure 1A) exhibited the 
highest elevation of Prdx1, Prdx2 and Prdx4. Prdx6 levels reached 
7X, while quantification of Prdx5 levels could not be made due to 
low signal.
We then quantified the number and percentage of patients who 
clearly (and unambiguously) showed elevated expression of each 
Prdx. As shown in Table 1, the first four Prdxs were elevated in 71%, 
50%, 64%, and 57% of patients, respectively. Finally, we quantified 
the number of patients exhibiting overexpression of multiple Prdx 
proteins. As shown in table 2, 64% of patients overexpressed two or 
more Prdxs in tumor tissue and 50% of patients overexpressed 4 or 
more Prdxs in tumor tissue. Of the 14 patients analyzed, we found 
only three patients who exhibited little to no Prdx elevation in tumor 
tissue (Figure 1A, P2; Figure1B, P3 & P4).
Based on prior conflicting studies regarding the relationship 
between Prdx levels and tumor grade, we wanted to examine this in our 
samples. The tumor grade for each patient was available from the blot 
supplier (Imgenex/Novus). We examined whether the incidence of Prdx 
overexpression correlated with tumor grade in these patient samples. 
As shown in Figure 1, we found Prdx overexpression in all four tumor 
grades (I, II, III and IV), and we saw no particular relationship between 
the tumor grade and the incidence of Prdx elevation for any of the Prdx 
proteins, as determined by correlation analysis.
Discussion
In the present study, we examined the expression of the six 
Peroxiredoxin antioxidant proteins in tumor tissue and adjacent 
normal tissue from 14 breast cancer patients. We found that the vast 
majority of patients show a marked overexpression of multiple Prdx 
proteins in tumor tissue, with Prdx1, 3 and 4 being most frequently 
elevated, and by the largest extent. We found no correlation between 
incidence of Prdx overexpression and tumor grade.
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Figure 1: Prdx Expression in Tumor (T) and Adjacent Normal (N) Tissue. (A) 
Oncopair INSTAblot IMB-130d, including matched tumor and adjacent non-
tumor breast tissue for 7 patient donors. Tumor diagnosis for patients are as 
follows: P1, mucinous carcinoma; P2, mucinous carcinoma; P3, mucinous 
carcinoma; P4, metaplastic; P5, intraductal carcinoma; P6, intraductal 
carcinoma; P7, intraductal carcinoma; (B) Oncopair INSTAblot IMB-130a, 
including matched tumor and adjacent non -tumor breast tissue for 7 patient 
donors. All breast tumors were diagnosed as ductal carcinoma. (*note – the 
patient orientation of this blot is reversed from the published order, based on 
a difference in loading order for this blot lot).
Table 1: Percent of Patients having elevated tumor Prdx Levels.
% (n = 14)
Prdx 1 71 (10/14)
Prdx 2 50 (7/14)
Prdx 3 64 (9/14)
Prdx 4 57 (8/14)
Prdx 5 14* (1/7)
*(n = 7)
Prdx 6 21 (3/14)
Table 2: Percent of Patients having elevated tumor Levels of Multiple Prdxs.
# of Prdx genes overexpressed % (n = 14)
2 or more 64
3 or more 50
4 or more 50
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Our findings are consistent with other studies that have examined 
multiple Prdxs, including studies that specifically found elevated 
expression of Prdx1-3 in breast tumors [9], and another showing 
elevation in Prdx1, 3, and 4 in a much higher percentage of breast 
cancer than either Prdx2 or Prdx6 [10]. However, these other studies 
used non-matched normal breast tissue as controls. Since Prdx levels 
vary significantly between individuals, our study demonstrating 
elevated tumor levels compared to normal breast tissue within the 
same individual is more compelling, and more strongly supports a 
physiologically important role for Prdx in the cancer process. Our 
observations that Prdx1-4 are elevated in most tumors are also 
consistent with our previous studies showing overexpression of 
Prdxs1 -5 (but not Prdx6) in the MCF7 breast cancer cell line, as 
compared to the normal MCF10A line [18,19]. This helps to validate 
the use of the MCF7/MCF10A cell lines as an acceptable in vitro model 
for further investigation of Prdx regulation and function in breast 
cancer. Despite considerable evidence that Prdxs are upregulated 
in breast cancer, as well as other cancers, there is virtually nothing 
known about the mechanism of this upregulation in these cells.
Our observation that Prdx1-4 are most commonly elevated in 
breast tumors is intriguing. A recent review explores new evidence 
on the mechanism of action of these 2-Cys peroxiredoxins (Prdx1-
4), revealing their important role in redox-sensitive processes 
including proliferation and cancer [20]. Each of these proteins uses 
a similar dimeric structure to catalyze the peroxide reaction, and 
has a somewhat distinct subcellular localization. Prdx1 has been the 
most studied, and is the most abundant Prdx in cells, localizing to the 
cytosol. Cha et al. reported overexpression of Prdx1 and Thioredoxin 
I in breast carcinoma, using paired samples, and further reported an 
association with tumor grade [21]. However, this study compared 
fold difference in mRNA levels (not protein) between tumor grade 
and type, and examined a much larger set of samples, so it is possible 
that we may have observed a correlation with a larger set of samples.
Prdx1 has been found to associate with multiple proteins 
including c-Abl [22], and recently, Prdx1 was shown to associate 
with MAPK phosphatases (MKP-1 and MKP-5), thereby regulating 
redox-signaling in breast cancer in a H202 dose-dependent manner 
[23]. Based on its dual-role, it is possible that upregulation of Prdx1 in 
breast cancer either serves to protect cancer cells from ROS-induced 
damage and/or assists in redox-regulated proliferation and apoptosis. 
Prdx2 is another cytoplasmic peroxiredoxin, while Prdx3 is the 
primary mitochondrial peroxiredoxin, which is critical for proper 
mitochondrial function [24]. Prdx4 is both secreted and found in the 
ER, and recently has been implicated in the oxidative protein folding 
[25,26]. While upregulation of all four of these peroxiredoxins has 
been reported in breast cancer cells, there is little known about their 
role in these tumor cells. It is clear that each Prdx has designated 
peroxide-detoxifying roles in the cell, and that levels of ROS in all 
of these subcellular locations are elevated in cancer cells. A recent 
report from our lab demonstrated that suppression of Prdxs 1,2,3 
or 5 in MCF7 breast cancer cells significantly reduces resistance to 
doxorubicin, while suppression of Prdx3 reduces cell viability even 
in the absence of drug treatment [18]. This is the only study, thus far, 
that has examined the effect of all six Prdx proteins in breast cancer 
cells.
Much additional research is needed to elucidate the precise 
role of each Prdx in breast cancer biology, and the mechanism of 
its upregulation in tumor cells. But together, our findings further 
implicate overexpression of the Prdx family of proteins in breast 
cancer as a widespread phenomenon, and support the notion that 
Prdx induction may provide cytoprotection for breast cancer cells in 
vivo.
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